ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Ramalingam on the Role of Osimertinib in EGFR T790M-Positive Advanced NSCLC

Suresh S. Ramalingam, MD
Published: Wednesday, Dec 07, 2016



Suresh S. Ramalingam, MD, professor, Department of Hematology and Medical Oncology, Deputy Director, Winship Cancer Institute of Emory University, discusses the role of osimertinib (Tagrisso) in the treatment of patients with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC), during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Osimertinib is a potent, irreversible, CNS active, EGFR TKI selective for sensitizing and T790M resistance mutations. The agent is currently indicated for the treatment of patients with locally advanced or metastatic EGFR T790M-positive NSCLC.

In the randomized AURA3 trial, patients who received osimertinib achieved a median progression-free survival of 10.1 months (95% CI, 8.3-12.3) compared with 4.4 months (95% CI, 4.2-5.6) for those treated with platinum chemotherapy plus pemetrexed (HR, 0.30; P <.001).

Osimertinib demonstrated a superior and clinically meaningful efficacy over platinum-pemetrexed in patients with EGFR T790M-positive advanced NSCLC, yielding a 70% reduction in the risk of disease progression and a favorable safety profile.

<<< View more from the IASLC 17th World Conference on Lung Cancer



Suresh S. Ramalingam, MD, professor, Department of Hematology and Medical Oncology, Deputy Director, Winship Cancer Institute of Emory University, discusses the role of osimertinib (Tagrisso) in the treatment of patients with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC), during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Osimertinib is a potent, irreversible, CNS active, EGFR TKI selective for sensitizing and T790M resistance mutations. The agent is currently indicated for the treatment of patients with locally advanced or metastatic EGFR T790M-positive NSCLC.

In the randomized AURA3 trial, patients who received osimertinib achieved a median progression-free survival of 10.1 months (95% CI, 8.3-12.3) compared with 4.4 months (95% CI, 4.2-5.6) for those treated with platinum chemotherapy plus pemetrexed (HR, 0.30; P <.001).

Osimertinib demonstrated a superior and clinically meaningful efficacy over platinum-pemetrexed in patients with EGFR T790M-positive advanced NSCLC, yielding a 70% reduction in the risk of disease progression and a favorable safety profile.

<<< View more from the IASLC 17th World Conference on Lung Cancer




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x